283 related articles for article (PubMed ID: 33730837)
1. [Advances in researches of serotype 2 novel oral polio vaccine].
Chen SY; Li Y; Yang JS; Yin XX
Zhonghua Yu Fang Yi Xue Za Zhi; 2021 Mar; 55(3):413-417. PubMed ID: 33730837
[TBL] [Abstract][Full Text] [Related]
2. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 Jun; 16():237. PubMed ID: 27246198
[TBL] [Abstract][Full Text] [Related]
3. Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2016 May; 16():231. PubMed ID: 27230071
[TBL] [Abstract][Full Text] [Related]
4. The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission.
Thompson KM; Duintjer Tebbens RJ
BMC Infect Dis; 2015 Sep; 15():376. PubMed ID: 26382234
[TBL] [Abstract][Full Text] [Related]
5. Assessing country compliance with circulating vaccine-derived poliovirus type 2 outbreak response standard operating procedures: April 2016 to December 2020.
Darwar R; Biya O; Greene SA; Jorba J; Al Safadi M; Franka R; Wiesen E; Durry E; Pallansch MA
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A25-A34. PubMed ID: 36863925
[TBL] [Abstract][Full Text] [Related]
6. Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response.
Kalkowska DA; Pallansch MA; Wassilak SGF; Cochi SL; Thompson KM
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A136-A141. PubMed ID: 33994237
[TBL] [Abstract][Full Text] [Related]
7. Updated Characterization of Post-OPV Cessation Risks: Lessons from 2019 Serotype 2 Outbreaks and Implications for the Probability of OPV Restart.
Kalkowska DA; Pallansch MA; Cochi SL; Kovacs SD; Wassilak SGF; Thompson KM
Risk Anal; 2021 Feb; 41(2):320-328. PubMed ID: 32632925
[TBL] [Abstract][Full Text] [Related]
8. Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences.
Kalkowska DA; Wassilak SGF; Wiesen E; Burns CC; Pallansch MA; Badizadegan K; Thompson KM
Risk Anal; 2024 Feb; 44(2):366-378. PubMed ID: 37344934
[TBL] [Abstract][Full Text] [Related]
9. Introduction of Inactivated Poliovirus Vaccine and Switch from Trivalent to Bivalent Oral Poliovirus Vaccine - Worldwide, 2013-2016.
Immunization Systems Management Group of the Global Polio Eradication Initiative
MMWR Morb Mortal Wkly Rep; 2015 Jul; 64(25):699-702. PubMed ID: 26135591
[TBL] [Abstract][Full Text] [Related]
10. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, July 2019-February 2020.
Alleman MM; Jorba J; Greene SA; Diop OM; Iber J; Tallis G; Goel A; Wiesen E; Wassilak SGF; Burns CC
MMWR Morb Mortal Wkly Rep; 2020 Apr; 69(16):489-495. PubMed ID: 32324719
[TBL] [Abstract][Full Text] [Related]
11. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine - Worldwide, 2016.
Hampton LM; Farrell M; Ramirez-Gonzalez A; Menning L; Shendale S; Lewis I; Rubin J; Garon J; Harris J; Hyde T; Wassilak S; Patel M; Nandy R; Chang-Blanc D;
MMWR Morb Mortal Wkly Rep; 2016 Sep; 65(35):934-8. PubMed ID: 27606675
[TBL] [Abstract][Full Text] [Related]
12. Implementing the Synchronized Global Switch from Trivalent to Bivalent Oral Polio Vaccines-Lessons Learned From the Global Perspective.
Ramirez Gonzalez A; Farrell M; Menning L; Garon J; Everts H; Hampton LM; Dolan SB; Shendale S; Wanyoike S; Veira CL; Châtellier GMD; Kurji F; Rubin J; Boualam L; Chang Blanc D; Patel M
J Infect Dis; 2017 Jul; 216(suppl_1):S183-S192. PubMed ID: 28838179
[TBL] [Abstract][Full Text] [Related]
13. Polio endgame: the global switch from tOPV to bOPV.
Garon J; Seib K; Orenstein WA; Ramirez Gonzalez A; Chang Blanc D; Zaffran M; Patel M
Expert Rev Vaccines; 2016 Jun; 15(6):693-708. PubMed ID: 26751187
[TBL] [Abstract][Full Text] [Related]
14. Updated Characterization of Outbreak Response Strategies for 2019-2029: Impacts of Using a Novel Type 2 Oral Poliovirus Vaccine Strain.
Kalkowska DA; Pallansch MA; Wilkinson A; Bandyopadhyay AS; Konopka-Anstadt JL; Burns CC; Oberste MS; Wassilak SGF; Badizadegan K; Thompson KM
Risk Anal; 2021 Feb; 41(2):329-348. PubMed ID: 33174263
[TBL] [Abstract][Full Text] [Related]
15. Analysis of population immunity to poliovirus following cessation of trivalent oral polio vaccine.
Voorman A; Lyons H; Bennette C; Kovacs S; Makam JK; F Vertefeuille J; Tallis G
Vaccine; 2023 Apr; 41 Suppl 1(Suppl 1):A85-A92. PubMed ID: 35339308
[TBL] [Abstract][Full Text] [Related]
16. Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use.
Duintjer Tebbens RJ; Hampton LM; Thompson KM
BMC Infect Dis; 2018 Apr; 18(1):165. PubMed ID: 29631539
[TBL] [Abstract][Full Text] [Related]
17. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2020-June 2021.
Alleman MM; Jorba J; Henderson E; Diop OM; Shaukat S; Traoré MA; Wiesen E; Wassilak SGF; Burns CC
MMWR Morb Mortal Wkly Rep; 2021 Dec; 70(49):1691-1699. PubMed ID: 34882653
[TBL] [Abstract][Full Text] [Related]
18. Evaluating cessation of the type 2 oral polio vaccine by modeling pre- and post-cessation detection rates.
Kroiss SJ; Famulare M; Lyons H; McCarthy KA; Mercer LD; Chabot-Couture G
Vaccine; 2017 Oct; 35(42):5674-5681. PubMed ID: 28890193
[TBL] [Abstract][Full Text] [Related]
19. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2018-June 2019.
Jorba J; Diop OM; Iber J; Henderson E; Zhao K; Quddus A; Sutter R; Vertefeuille JF; Wenger J; Wassilak SGF; Pallansch MA; Burns CC
MMWR Morb Mortal Wkly Rep; 2019 Nov; 68(45):1024-1028. PubMed ID: 31725706
[TBL] [Abstract][Full Text] [Related]
20. Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation.
Thompson KM; Kalkowska DA; Badizadegan K
Front Public Health; 2023; 11():1098419. PubMed ID: 37033033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
